Prasugrel gains NICE approval

The UK's drug guidance body has endorsed the use of prasugrel (Efient) in patients with acute coronary syndromes who are undergoing percutaneous coronary intervention.

by
Prasugrel (Efient) prevents clot formation by binding to the P2Y12 ADP receptor on the surface of platelets, thereby inhibiting platelet activation and aggregation.
Prasugrel (Efient) prevents clot formation by binding to the P2Y12 ADP receptor on the surface of platelets, thereby inhibiting platelet activation and aggregation.

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package